JAZZJazz Pharmaceuticals plc

Nasdaq jazzpharma.com


$ 120.92 $ 0.18 (0.15 %)    

Thursday, 28-Mar-2024 15:39:58 EDT
QQQ $ 444.66 $ -0.02 (-0.01 %)
DIA $ 398.21 $ 0.02 (0.01 %)
SPY $ 524.16 $ 0.91 (0.17 %)
TLT $ 94.62 $ 0.18 (0.19 %)
GLD $ 205.45 $ 0.50 (0.24 %)
$ 120.51
$ 120.74
$ 0.00 x 0
$ 0.00 x 0
$ 120.04 - $ 121.53
$ 111.25 - $ 147.98
471,653
na
8.68B
$ 0.70
$ 20.94
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-28-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-10-2023 03-31-2023 10-Q
5 03-01-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-03-2022 06-30-2022 10-Q
8 05-04-2022 03-31-2022 10-Q
9 03-01-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-03-2021 06-30-2021 10-Q
12 05-04-2021 03-31-2021 10-Q
13 02-23-2021 12-31-2020 10-K
14 11-02-2020 09-30-2020 10-Q
15 08-04-2020 06-30-2020 10-Q
16 05-05-2020 03-31-2020 10-Q
17 02-25-2020 12-31-2019 10-K
18 11-05-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-07-2019 03-31-2019 10-Q
21 02-26-2019 12-31-2018 10-K
22 11-06-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-08-2018 03-31-2018 10-Q
25 02-27-2018 12-31-2017 10-K
26 11-07-2017 09-30-2017 10-Q
27 08-08-2017 06-30-2017 10-Q
28 05-09-2017 03-31-2017 10-Q
29 02-28-2017 12-31-2016 10-K
30 11-08-2016 09-30-2016 10-Q
31 08-09-2016 06-30-2016 10-Q
32 05-10-2016 03-31-2016 10-Q
33 02-23-2016 12-31-2015 10-K
34 11-09-2015 09-30-2015 10-Q
35 08-05-2015 06-30-2015 10-Q
36 05-07-2015 03-31-2015 10-Q
37 02-24-2015 12-31-2014 10-K
38 11-04-2014 09-30-2014 10-Q
39 08-05-2014 06-30-2014 10-Q
40 05-08-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-jazz-pharmaceuticals-maintains-180-price-target

Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and maintains $180 ...

 truist-securities-reiterates-buy-on-jazz-pharmaceuticals-maintains-200-price-target

Truist Securities analyst Joon Lee reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $200 price target.

 piper-sandler-reiterates-overweight-on-jazz-pharmaceuticals-raises-price-target-to-188

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price ta...

 piper-sandler-maintains-overweight-on-jazz-pharmaceuticals-raises-price-target-to-188

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price tar...

 needham-reiterates-buy-on-jazz-pharmaceuticals-maintains-220-price-target

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $220 price target.

 stifel-maintains-buy-on-jazz-pharmaceuticals-raises-price-target-to-230

Stifel analyst Annabel Samimy maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $225 ...

 hc-wainwright--co-maintains-buy-on-jazz-pharmaceuticals-lowers-price-target-to-200

HC Wainwright & Co. analyst Oren Livnat maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price tar...

Core News & Articles

Avadel Pharmaceuticals plc (NASDAQ:AVDL), today issued a statement in response to a jury ruling from the United States District...

 cantor-fitzgerald-reiterates-overweight-on-jazz-pharmaceuticals-maintains-180-price-target

Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and maintains $180 ...

 rbc-capital-reiterates-outperform-on-jazz-pharmaceuticals-maintains-195-price-target

RBC Capital analyst Gregory Renza reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and maintains $195 price t...

 jp-morgan-maintains-overweight-on-jazz-pharmaceuticals-lowers-price-target-to-170

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target fro...

 needham-maintains-buy-on-jazz-pharmaceuticals-lowers-price-target-to-220

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $225 to $...

 jazz-pharmaceuticals-q4-2023-adj-eps-502-misses-518-estimate-sales-101b-beat-100b-estimate

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $5.02 per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION